WINNERSH, England, Dec. 11 /PRNewswire-FirstCall/ -- Vernalis plc (LSE: VERLSE:Nasdaq:LSE:VNLS) today announced that it has started a Phase I trial of V24343, a CB1 antagonist, as a potential...
WINNERSH, England, Nov. 21 /PRNewswire-FirstCall/ -- Vernalis plc (LSE: VER)(NASDAQ:VNLS), a specialty bio-pharmaceutical and drug development company, today announced that Simon Sturge, Chief...
WINNERSH, England, Nov. 20 /PRNewswire-FirstCall/ -- Vernalis plc (LSE:VERLSE:Nasdaq:LSE:VNLS), a specialty bio-pharmaceutical and drug development company, today announced that Novartis has...
WINNERSH, England, Nov. 2 /PRNewswire/ -- Vernalis plc (LSE:VERLSE:Nasdaq:LSE:VNLS), a specialty bio-pharmaceutical and drug development company, today announced that Simon Sturge, Chief...
WINNERSH, U.K., Sept. 20 /PRNewswire-FirstCall/ -- Vernalis plc (LSE:VER) (NASDAQ:VNLS), a specialty bio-pharmaceutical and drug development company, today announced that Simon Sturge, Chief...
WINNERSH, England, Sept. 20 /PRNewswire-FirstCall/ -- Vernalis plc (LSE:VERLSE:Nasdaq:LSE:VNLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the...
- Vernalis Delivers on Significant Clinical Milestones and Establishes Commercial Operation - WINNERSH, England, Sept. 12 /PRNewswire-FirstCall/ -- Vernalis plc (LSE:VERLSE:Nasdaq:LSE:VNLS...
CHADDS FORD, Pa. and WINNERSH, U.K., July 19 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals Holdings Inc. (NASDAQ:ENDP) and Vernalis plc (NASDAQ:VNLS) (LONDON: VER) today announced that Endo...
WINNERSH, England, June 19 /PRNewswire-FirstCall/ -- Vernalis plc (NASDAQ:VNLS)(LSE:VER), a specialty bio-pharmaceutical and drug development company, today announced that Simon Sturge, Chief...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約